Enanta Pharmaceuticals Inc 8-K Filing
Ticker: ENTA · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Nov 17, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Enanta Pharmaceuticals Inc (ticker: ENTA) to the SEC on Nov 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select).
How long is this filing?
Enanta Pharmaceuticals Inc's 8-K filing is 1 pages with approximately 447 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-11-17 16:15:28
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
Filing Documents
- enta-20251117.htm (8-K) — 43KB
- enta-ex99_1.htm (EX-99.1) — 275KB
- img152620751_0.jpg (GRAPHIC) — 16KB
- 0001193125-25-284633.txt ( ) — 457KB
- enta-20251117.xsd (EX-101.SCH) — 23KB
- enta-20251117_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 17, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of Enanta Pharmaceuticals, Inc. dated November 17, 2025, reporting Enanta's financial results for the fiscal quarter and year ended September 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: November 17, 2025 By: /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer